Literature DB >> 27429035

Increased Esophageal Exposure to Weakly Acidic Reflux 5 Years After Laparoscopic Roux-en-Y Gastric Bypass.

Fabrizio Rebecchi1, Marco E Allaix, Elettra Ugliono, Claudio Giaccone, Mauro Toppino, Mario Morino.   

Abstract

OBJECTIVE: To evaluate the long-term effects of laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on gastroesophageal function.
BACKGROUND: LRYGB is considered the weight loss procedure of choice for obese patients with gastroesophageal reflux disease (GERD). However, long-term instrumental evaluations of GERD after LRYGB are not available.
METHODS: Morbidly obese patients selected for LRYGB were included in a prospective study. We performed clinical evaluation with GERD-HRQoL questionnaire, upper endoscopy, esophageal manometry, and 24-hour impedance pH (24-hour MII-pH) monitoring preoperatively and at 12 and 60 months after surgery. This trial is registered with ClinicalTrials.gov (no. NCT02618044).
RESULTS: From May 2006 to May 2009, 86 patients entered the study and 72 (84%) completed the 5-year protocol. At preoperative 24-hour MII-pH monitoring, 54 patients (group A) had normal values, whereas 32 (group B) had diagnosis of GERD: 23 had acidic reflux, whereas 9 had combined reflux [acidic + weakly acidic reflux (WAR)]. The groups were similar in preoperative age, body mass index, and comorbidities. At 12 and 60 months, significant improvement in questionnaire scores was observed in group B patients. No manometric changes occurred in both groups; 24-hour MII-pH monitoring showed a significant reduction in acid exposure, but an increase of WAR in both group A (from 0% to 52% to 74%) and group B (from 35% to 42% to 77%). At long-term follow-up, esophagitis was found in 14 group A (30%) and in 18 group B patients (69%) (P < 0.001).
CONCLUSIONS: LRYGB allows to obtain an effective GERD symptom amelioration and a reduction in acid exposure. However, 3 out 4 patients present with distal esophagus exposure to WAR.

Entities:  

Mesh:

Year:  2016        PMID: 27429035     DOI: 10.1097/SLA.0000000000001775

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  6 in total

1.  Outcomes of Long Pouch Gastric Bypass (LPGB): 4-Year Experience in Primary and Revision Cases.

Authors:  Rui Ribeiro; Sjaak Pouwels; Chetan Parmar; João Pereira; Leonor Manaças; Anabela Guerra; Nuno Borges; João Ribeiro; Octávio Viveiros
Journal:  Obes Surg       Date:  2019-11       Impact factor: 4.129

2.  Reflux, Sleeve Dilation, and Barrett's Esophagus after Laparoscopic Sleeve Gastrectomy: Long-Term Follow-Up.

Authors:  Daniel Moritz Felsenreich; Ronald Kefurt; Martin Schermann; Philipp Beckerhinn; Ivan Kristo; Michael Krebs; Gerhard Prager; Felix B Langer
Journal:  Obes Surg       Date:  2017-12       Impact factor: 4.129

3.  Clinical Endoscopic and Histologic Findings of a Long-Term Follow-Up (10.7 Years) After Roux-en-Y Laparoscopic Gastric Bypass: a Prospective Study.

Authors:  Attila J Csendes; Deycies L Gaete; Bárbara M Carreño; Benjamín Panza
Journal:  Obes Surg       Date:  2022-07-01       Impact factor: 3.479

4.  Robotic Roux-en-Y Gastric Bypass as a Revisional Bariatric Procedure: a Single-Center Prospective Cohort Study.

Authors:  Fabrizio Rebecchi; Elettra Ugliono; Marco Ettore Allaix; Mauro Toppino; Alessandro Borello; Mario Morino
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

5.  Combined partial posterior fundoplication with laparoscopic sleeve gastrectomy for morbid obese patients with symptomatic GERD. Video case report.

Authors:  Ozan Şen; Ahmet Gökhan Türkçapar
Journal:  Int J Surg Case Rep       Date:  2020-05-08

6.  Esophageal Pathophysiologic Changes and Adenocarcinoma After Bariatric Surgery: A Systematic Review and Meta-Analysis.

Authors:  Veeravich Jaruvongvanich; Reem Matar; Karthik Ravi; M Hassan Murad; Kornpong Vantanasiri; Nicha Wongjarupong; Patompong Ungprasert; Eric J Vargas; Daniel B Maselli; Larry J Prokop; Barham K Abu Dayyeh
Journal:  Clin Transl Gastroenterol       Date:  2020-08       Impact factor: 4.396

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.